Stable Angina Clinical Trial
Official title:
Comparison of Clinical Outcomes Between Imaging and Physiology-guided Intervention Strategy in Patients With Intermediate Stenosis: Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis (FLAVOUR)
To compare the safety and efficacy of FFR (fractional flow reserve)-guided percutaneous coronary intervention (PCI) strategy with IVUS (intravascular ultrasound [IVUS])-guided PCI in patients with intermediate coronary stenosis.
1. Study overview This study is a prospective, open-label, randomized, multicenter trial to
test the safety and efficacy of physiology- or imaging-guided PCI in patients with
intermediate coronary stenosis.
The primary hypothesis is that FFR-guided strategy will show non-inferior rate of
patients-oriented composite outcomes (POCO) at 24 months after randomization, compared
with IVUS-guided strategy in patients with intermediate coronary stenosis.
2. Study population and sample size calculation
Sample Size Calculation Based on the event rates of previous trials, investigators
predicted the rates of POCO at 24 months after PCI will be 10% in the FFR-guided arm,
and 12% in the IVUS-guided arm.
- Primary endpoint: patient-oriented composite outcome (a composite of all-cause
death, MI, any repeat revascularization) at 24 months after PCI
- Design: non-inferiority , delta = 2.5%
- Sampling ratio: FFR-guided strategy : IVUS-guided strategy = 1:1
- Type I error (α): One-sided 5%
- Accrual time : 2 years
- Total time : 4 years (accrual 2 year + follow-up 2 years)
- Assumption: POCO 10.0% vs. 12.0% in FFR or IVUS-guided strategy, respectively
- Statistical power (1- β): 90%
- Primary statistical method : Kaplan-Meier survival analysis with log-rank test
- Potential withdrawal rates : total 2%
- Stratification in Randomization: Presence of Diabetes Mellitus (600 patients (35%)
will be Diabetic patients, with 300 patients in each group)
Based on the above assumption, 1,700 patients (850 patients in each group) will be
enrolled in this study with consideration of withdrawal rates.
3. Research Materials and Indication for Revascularization For the FFR-guided strategy arm,
a pressure-sensor wire system will be used and the criterion for revascularization is
FFR ≤ 0.80. Hyperemia will be induced by intravenous infusion of adenosine
(140ug/kg/min). For the IVUS-guided strategy arm, the criterion for revascularization is
MLA ≤ 3mm2 or [3mm2 < MLA ≤ 4mm2 and plaque burden > 70%].
4. Funding This is an investigator-initiated study with grant support from Boston
Scientific. Other than financial sponsorship, the company has no role in protocol
development or the implementation, management, data collection, and analysis of this
study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Not yet recruiting |
NCT02550301 -
Does Mean Platelet Volume Change With Clopidogrel
|
N/A | |
Completed |
NCT02252406 -
Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT02244853 -
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT01162902 -
Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation
|
Phase 4 | |
Completed |
NCT01826552 -
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
|
Phase 4 | |
Completed |
NCT02126150 -
United Coronary Biobanks
|
N/A | |
Completed |
NCT01769079 -
Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina
|
Phase 4 | |
Completed |
NCT01328470 -
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
|
Phase 4 | |
Unknown status |
NCT00751491 -
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
Completed |
NCT00263263 -
RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.
|
Phase 2 | |
Active, not recruiting |
NCT04929496 -
Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Recruiting |
NCT05459051 -
Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
|
||
Completed |
NCT06464276 -
Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
|
||
Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
Completed |
NCT01974492 -
Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting
|
N/A | |
Completed |
NCT02120859 -
Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty
|
Phase 4 | |
Completed |
NCT01990924 -
Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention
|
N/A |